Navigation Links
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.

"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) stud
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
4. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
5. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... According to a new ... Devices Market (Embolic Protection, Chronic Total Occlusion, Atherectomy, ... Filters, Stents, Balloons and Accessories) - Forecasts to ... Peripheral Vascular Devices Market is expected to reach ... of 7.4% from 2014 to 2019. ...
(Date:6/3/2015)...  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a leading ... surgery (MIS) announced today that surgeons have successfully ... Adoption has risen rapidly with a 150% growth ... the company,s expansion from robotics into the general ... over 45 countries.   The AirSeal ...
(Date:6/3/2015)... , June 3, 2015 PillPack, the pharmacy ... a $50 million round of financing led by CRV ... and Sherpa Ventures. The capital will be used to ... and build retail pharmacies in US markets. ... a better, simpler pharmacy experience that folks absolutely love," ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... , MELBOURNE, Australia, Nov. 18 ... pleased to announce a successful capital raising of A$15.6 ... investors, taking the company,s cash reserves to approximately A$24 ... Orbis, an existing Starpharma shareholder and a highly regarded ...
... Nov. 18 Rules-Based Medicine, Inc. (RBM) today announced it ... Covance Inc. (NYSE: CVD ) that will provide ... technologies and services for use in drug development. Under terms ... third-party provider of multiplexed protein biomarker testing services, and RBM ...
Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... Pittsburgh, PA (PRWEB) June 03, 2015 ... basis can cause discomfort in the back, neck, shoulders ... or other musculoskeletal injuries. In addition, recent research links ... a number of chronic diseases. Fortunately, three inventors from ... than sit at a desk. , They have developed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... to turn back the clock on aging stem cells ... in a fracture every three seconds worldwide, according to ... the right signals could help aging stem cells act ... death and disability associated with a frail framework, Georgia ...
... WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and ... the popular statin Zocor because of an increased risk of ... This risk has been seen among some people taking 80 ... year of treatment, the agency said. In light of this, ...
... winter 2009-2010 was much more widespread than was previously realised, research ... year at the end of the H1N1 flu season showed that ... of the 44 per cent who tested positive had contracted swine ... flu, or had been vaccinated. The research, led by ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, June 8 (HealthDay ... may be available in the United States as soon as this ... for the scans to be of much help for those ... earlier diagnosis, which can be important to people who want to ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- Girls ... explain some cases of autism in families with no history ... a certain number of duplications or deletions of one or ... explained Dr. Christian Schaaf, an assistant professor in the department ...
... The University of Alabama at Birmingham has taken a ... patient care with its acquisition of the first cell-processing workstation ... States. Richard Marchase, Ph.D., vice president for Research ... history of breaking ground in the cell-therapy arena. We are ...
Cached Medicine News:Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 3Health News:Girls May Be More Resistant to Autism Than Boys: Study 4Health News:UAB first in US with cell-processing workstation 2Health News:UAB first in US with cell-processing workstation 3
Reciprocating shaker specifically for platelet bags....
... quantitative determination of progesterone ... Progesterone EIA is ... of competitive binding between ... specimen and progesterone-HRP conjugate ...
... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
... Labcold platelet incubators provide accurate and ... have incorporated all of the same ... are found in the Labcold BS ... levels of product security. An independent ...
Medicine Products: